Delivery Order SPE2DB20D1100-SPE2DB25FE2T5
- Not listed
- The Defense Logistics Agency awarded a $11,086.64 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors (0.5 mL), a GLP-1 receptor agonist medication used for weight management. This firm fixed price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,928.55 to AmerisourceBergen Drug Corp for ZEPBOUND 2.5 MG/0.5 ML Pen 0.5ML, a GLP-1 receptor agonist medication used for weight management. The contract, awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, was competitively awarded without set-aside designation and carries firm fixed pricing. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,213.05 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. The contract was awarded on July 16, 2025, with an ultimate completion date of July 17, 2025, and utilizes firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office...
- The Defense Logistics Agency awarded a $9,725.21 delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used in diabetes and weight management treatment. This firm fixed-price, competitively awarded delivery order is set to be completed by August 7, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $7,218.52 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 ml pen injections (0.5 ml), a GLP-1 receptor agonist medication used for weight management. The contract, executed on August 26, 2025, with completion targeted for August 27, 2025, utilizes firm fixed-price pricing under a non-set-aside competitive procurement. Performance will be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used for weight management. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,050.40 and an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,575.48 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. The contract was awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, and represents a competitively awarded, firm fixed-price transaction with no set-aside designation. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,906.47 for Zepbound 2.5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $12,879.01 for Zepbound 5 mg/0.5 mL pen injectors, a GLP-1 receptor agonist medication used for weight management. This firm fixed-price delivery order, issued on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The contract utilizes no set-aside designation, indicating open...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE2T5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,234.96 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen (0.5ml), a GLP-1 receptor agonist medication used for weight management. The contract is a firm fixed-price delivery order with no set-aside designation, awarded on August 26, 2025, with an ultimate completion date of August 27, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026, which serves as a comprehensive pharmaceutical supply vehicle for military and federal healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains extensive federal contracts with the Defense Logistics Agency supplying a broad portfolio of medications and medical supplies to support military healthcare operations globally. The company's competitively awarded contracts demonstrate its capability to fulfill federal medical procurement requirements across multiple therapeutic domains. This particular delivery order supports the Defense Health Agency and other federal healthcare customers requiring specialty pharmaceutical products for troop readiness and veteran care programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/26/25 |